Cargando…

Dose escalation study of proton beam therapy with concurrent chemotherapy for stage III non‐small cell lung cancer

The purpose of this study is to determine the recommended dose (RD) of proton beam therapy (PBT) for inoperable stage III non‐small cell lung cancer (NSCLC). We tested two prescribed doses of PBT: 66 Gy (relative biological effectiveness [RBE]) in 33 fractions and 74 Gy (RBE) in 37 fractions in arms...

Descripción completa

Detalles Bibliográficos
Autores principales:	Harada, Hideyuki, Fuji, Hiroshi, Ono, Akira, Kenmotsu, Hirotsugu, Naito, Tateaki, Yamashita, Haruo, Asakura, Hirofumi, Nishimura, Tetsuo, Takahashi, Toshiaki, Murayama, Shigeyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946725/ https://www.ncbi.nlm.nih.gov/pubmed/27110950 http://dx.doi.org/10.1111/cas.12955

Ejemplares similares

Assessment of organ dose reduction and secondary cancer risk associated with the use of proton beam therapy and intensity modulated radiation therapy in treatment of neuroblastomas
por: Fuji, Hiroshi, et al.
Publicado: (2013)

A simpler method for total scalp irradiation: the multijaw‐size concave arc technique
por: Inoue, Minoru, et al.
Publicado: (2014)

Impact of Interstitial Lung Disease Classification on the Development of Acute Exacerbation of Interstitial Lung Disease and Prognosis in Patients with Stage III Non-Small-Cell Lung Cancer and Interstitial Lung Disease Treated With Chemoradiotherapy
por: Kobayashi, Haruki, et al.
Publicado: (2018)

Palliative cerebrospinal fluid shunting for leptomeningeal metastasis-related hydrocephalus in patients with lung adenocarcinoma: A single-center retrospective study
por: Mitsuya, Koichi, et al.
Publicado: (2019)

Primary malignant melanoma of the trachea: A case report
por: IMAI, HISAO, et al.
Publicado: (2015)

Chemoradiotherapy for limited-stage small-cell lung cancer and interstitial lung abnormalities
por: Kobayashi, Haruki, et al.
Publicado: (2021)

Re-irradiation for locoregionally recurrent tumors of the thorax: a single-institution, retrospective study
por: Sumita, Kiyomi, et al.
Publicado: (2016)

Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy
por: Akamatsu, Hiroaki, et al.
Publicado: (2014)

Incidence and Treatment Outcome of Radiation Pneumonitis in Patients With Limited-stage Small Cell Lung Cancer Treated With Concurrent Accelerated Hyperfractionated Radiation Therapy and Chemotherapy
por: Doshita, Kosei, et al.
Publicado: (2022)

Clinical and radiation dose-volume factors related to pneumonitis after treatment with radiation and durvalumab in locally advanced non-small cell lung cancer
por: Inoue, Hiroto, et al.
Publicado: (2020)

Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancer
por: Nishimura, Ari, et al.
Publicado: (2021)

Clinical impact of post-progression survival on overall survival in patients with limited-stage disease small cell lung cancer after first-line chemoradiotherapy
por: Kasahara, Norimitsu, et al.
Publicado: (2015)

Prognostic significance of diabetes mellitus in locally advanced non-small cell lung cancer
por: Imai, Hisao, et al.
Publicado: (2015)

Efficacy and safety of carboplatin and etoposide in older extensive‐stage small‐cell lung cancer patients with a poor performance status
por: Mamesaya, Nobuaki, et al.
Publicado: (2023)

Acquired immunodeficiency associated with thymoma: a case report
por: Kawamura, Takahisa, et al.
Publicado: (2019)

The effects of advanced age and serum α(1)‐acid glycoprotein on docetaxel unbound exposure and dose‐limiting toxicity in cancer patients
por: Kenmotsu, Hirotsugu, et al.
Publicado: (2017)

Proton beam therapy in non-small cell lung cancer: state of the art
por: Harada, Hideyuki, et al.
Publicado: (2017)

Reirradiation of spinal metastases with intensity-modulated radiation therapy: an analysis of 23 patients
por: Kawashiro, Shohei, et al.
Publicado: (2016)

Proposing synchronous oligometastatic non–small‐cell lung cancer based on progression after first‐line systemic therapy
por: Miyawaki, Taichi, et al.
Publicado: (2020)

Prognostic impact of serum CYFRA 21–1 in patients with advanced lung adenocarcinoma: a retrospective study
por: Ono, Akira, et al.
Publicado: (2013)

Negative impact of malignant effusion on osimertinib treatment for non-small cell lung cancer harboring EGFR mutation
por: Kawamura, Takahisa, et al.
Publicado: (2019)

Comparison of clinical features between immune-related sclerosing cholangitis and hepatitis
por: Takinami, Masaki, et al.
Publicado: (2021)

Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study
por: Miyawaki, Taichi, et al.
Publicado: (2021)

Comparison of platinum combination re-challenge therapy and docetaxel monotherapy in non-small cell lung cancer patients previously treated with platinum-based chemoradiotherapy
por: Imai, Hisao, et al.
Publicado: (2015)

Efficacy of prophylactic cranial irradiation in patients with limited-disease small-cell lung cancer who were confirmed to have no brain metastasis via magnetic resonance imaging after initial chemoradiotherapy
por: Mamesaya, Nobuaki, et al.
Publicado: (2018)

Desensitizing Effect of Cancer Cachexia on Immune Checkpoint Inhibitors in Patients With Advanced NSCLC
por: Miyawaki, Taichi, et al.
Publicado: (2020)

Isolation and molecular analysis of circulating tumor cells from lung cancer patients using a microfluidic chip type cell sorter
por: Watanabe, Masaru, et al.
Publicado: (2018)

Rebiopsy for patients with non‐small‐cell lung cancer after epidermal growth factor receptor‐tyrosine kinase inhibitor failure
por: Kawamura, Takahisa, et al.
Publicado: (2016)

Clinical impact of tumour burden on the efficacy of PD‐1/PD‐L1 inhibitors plus chemotherapy in non‐small‐cell lung cancer
por: Miyawaki, Taichi, et al.
Publicado: (2022)

Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer
por: Imai, Hisao, et al.
Publicado: (2015)

Proton beam therapy for pediatric malignancies: a retrospective observational multicenter study in Japan
por: Mizumoto, Masashi, et al.
Publicado: (2016)

Preliminary results of proton radiotherapy for pediatric rhabdomyosarcoma: a multi‐institutional study in Japan
por: Mizumoto, Masashi, et al.
Publicado: (2018)

Predicting the efficacy of first‐line immunotherapy by combining cancer cachexia and tumor burden in advanced non‐small cell lung cancer
por: Miyawaki, Taichi, et al.
Publicado: (2022)

Microdosimetric calculation of relative biological effectiveness for design of therapeutic proton beams(†)
por: Kase, Yuki, et al.
Publicado: (2013)

Feasibility of linac-based fractionated stereotactic radiotherapy and stereotactic radiosurgery for patients with up to ten brain metastases
por: Hirata, Masanori, et al.
Publicado: (2022)

Correction: Feasibility of linac-based fractionated stereotactic radiotherapy and stereotactic radiosurgery for patients with up to ten brain metastases
por: Hirata, Masanori, et al.
Publicado: (2023)

Long‐term follow‐up after proton beam therapy for pediatric tumors: a Japanese national survey
por: Mizumoto, Masashi, et al.
Publicado: (2017)

Erratum to ‘Microdosimetric calculation of relative biological effectiveness for design of therapeutic proton beams’(†)
por: Kase, Yuki, et al.
Publicado: (2013)

Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients
por: Ko, Ryo, et al.
Publicado: (2016)

Unfavorable impact of decreased muscle quality on the efficacy of immunotherapy for advanced non‐small cell lung cancer
por: Nishioka, Naoya, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_kr0869k1oggk2f6v38ipgqlif6